TLR8 aggravates skin inflammation and fibrosis by activating skin fibroblasts in systemic sclerosis
56 views | Nov 17 2023
The study demonstrates that Toll-like receptor 8 (TLR8) plays a pivotal role in promoting skin inflammation and fibrosis in systemic sclerosis (SSc), potentially offering a promising therapeutic target for improving SSc treatment strategies.
[Read the Full Post]
Non-oncology drug (meticrane) shows anti-cancer ability in synergy with epigenetic inhibitors and appears to be involved passively in targeting cancer cells
264 views | Nov 17 2023
Meticrane, a non-oncology drug originally used to treat hypertension, exhibits promising anti-cancer effects on leukemia and liver cancer cells, including synergistic interactions with epigenetic inhibitors, alterations in gene expression associated with non-cancer pathways, and considerable binding affinity to key cancer-related proteins, although it does not enhance the cytotoxicity of cytokine-induced killer cells, suggesting its potential as a novel cancer therapy warrants further investigation. [Read the Full Post]
Peripheral Activation of Formyl Peptide Receptor 2/ALX by Electroacupuncture Alleviates Inflammatory Pain by Increasing Interleukin-10 Levels and Catalase Activity in Mice
48 views | Nov 17 2023
The study demonstrates that the antihyperalgesic effect of electroacupuncture in a persistent inflammatory pain model may be associated with increased IL-10 levels and enhanced catalase activity in inflamed tissue, potentially mediated by peripheral FPR2/ALX activation.
[Read the Full Post]
The Novel, Orally Bioavailable CDK9 Inhibitor Atuveciclib Sensitises Pancreatic Cancer Cells to TRAIL-induced Cell Death
64 views | Nov 16 2023
This study demonstrates that the combination of Atuveciclib and TRAIL effectively reduces the viability of pancreatic ductal adenocarcinoma (PDAC) cells, inducing apoptosis and cell-cycle arrest, thus suggesting its potential as a promising therapeutic strategy for PDAC treatment, including resistant and patient-derived xenograft (PDX) cell lines.
[Read the Full Post]
Nuciferine protects against lipopolysaccharide-induced endometritis via inhibiting ferroptosis and modulating AMPKα/mTOR/HIF-1α signaling axis
90 views | Nov 16 2023
Nuciferine (NF) demonstrates protective effects against lipopolysaccharide (LPS)-induced endometritis in mice by modulating multiple pathways, including MyD88/NF-κB, MAPK, ferroptosis, and the AMPKα/mTOR/HIF1α signaling axis, while also exerting direct anti-inflammatory effects in endometrial epithelial cells through the inhibition of the NF-κB signaling pathway.
[Read the Full Post]
PHA-680626 Is an Effective Inhibitor of the Interaction between Aurora-A and N-Myc
78 views | Nov 16 2023
The study identifies PHA-680626 as a dual-function inhibitor capable of disrupting the AURKA/N-Myc interaction, offering a promising therapeutic strategy for treating neuroblastoma by destabilizing this oncogenic complex.
[Read the Full Post]
Evaluation of Histone Demethylase Inhibitor ML324 and Acyclovir against Cyprinid herpesvirus 3 Infection
149 views | Nov 16 2023
ML324, a specific inhibitor of JMJD2 histone demethylase, has demonstrated promising potential as a treatment against CyHV-3 infection in koi fish, effectively inhibiting viral replication both in vitro and in vivo. [Read the Full Post]
Endotyping of IgE-Mediated Polyethylene Glycol and/or Polysorbate 80 Allergy
39 views | Nov 16 2023
The study found that patients with allergies to polyethylene glycol (PEG) and polysorbate 80 (PS80) can safely receive the PEGylated lipid nanoparticle (LNP) COVID-19 vaccine BNT162b2, with cross-reactivity between PEG and PS80 being mediated by IgE recognizing short PEG motifs. [Read the Full Post]
Pin1 inhibitor API-1 sensitizes BRAF-mutant thyroid cancers to BRAF inhibitors by attenuating HER3-mediated feedback activation of MAPK/ERK and PI3K/AKT pathways
86 views | Nov 15 2023
The study demonstrates that the Pin1 inhibitor API-1 enhances the sensitivity of BRAF-mutant thyroid cancer cells to the BRAF inhibitor PLX4032 by blocking the reactivation of MAPK/ERK and PI3K/AKT pathways via downregulation of HER3, offering a promising combination therapy for this cancer type. [Read the Full Post]
Multi-omics analysis reveals the association between elevated KIF18B expression and unfavorable prognosis, immune evasion, and regulatory T cell activation in nasopharyngeal carcinoma
91 views | Nov 15 2023
Kinesin Family Member 18B (KIF18B) overexpression in Nasopharyngeal Carcinoma (NPC) is associated with poor prognosis, immune suppression, epithelial-mesenchymal transition (EMT), N6-methyladenosine (m6A) modification, and resistance to both immunotherapy and chemotherapy, making it a significant prognostic marker with potential therapeutic implications. [Read the Full Post]
Stearoyl-CoA desaturase-1 is required for flavivirus RNA replication
46 views | Nov 15 2023
Stearoyl-CoA desaturase-1 (SCD1) inhibitors, such as MK8245 and #1716, have shown potent and broad-spectrum suppression of Dengue virus replication, suggesting their potential as novel antiviral candidates for treating dengue fever and related flavivirus infections. [Read the Full Post]
FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models
70 views | Nov 15 2023
FASN inhibition demonstrates promising potential as a therapeutic strategy for NASH by targeting multiple hallmarks of the disease, including reducing hepatic fat accumulation, mitigating inflammation, and attenuating fibrosis. [Read the Full Post]
IL-17 Is a Key Regulator of Mucin-Galectin-3 Interactions in Asthma
100 views | Nov 15 2023
Galectin-3 (Gal-3) appears to play a pivotal role in the pathogenesis of asthma by regulating airway inflammation and mucin gene expression, suggesting that targeting Gal-3 could be a promising therapeutic strategy for the disease. [Read the Full Post]
AZD5438 a GSK-3a/b and CDK inhibitor is antiapoptotic modulates mitochondrial activity and protects human neurons from mitochondrial toxins
60 views | Nov 14 2023
The study suggests that AZD5438, a compound targeting GSK-3a/b and CDKs, holds significant therapeutic potential due to its ability to prevent mitochondrial dysfunction, promote neuroprotection, and enhance glycolytic respiration, particularly in neuronal cells. [Read the Full Post]
Inhibition of exchange proteins directly activated by cAMP as a strategy for broad-spectrum antiviral development
52 views | Nov 14 2023
The study demonstrates that EPAC antagonists like ESI-09 hold promise as broad-spectrum antiviral therapies, offering robust protection against various viruses and potential contributions to pandemic preparedness. [Read the Full Post]
Analysis of the ERK Pathway Cysteinome for Targeted Covalent Inhibition of RAF and MEK Kinases
0 views | Nov 14 2023
This research investigates the potential for covalent inhibitors targeting specific cysteine residues in key kinases of the ERK pathway to overcome resistance mechanisms and enhance the efficacy of cancer treatment. [Read the Full Post]
Virtual screening indicates potential inhibitors of the P2X7 receptor
64 views | Nov 14 2023
The passage discusses the search for natural and synthetic anti-inflammatory compounds, highlighting the identification of potential P2X7 receptor inhibitors, including flavonoids and drugs, through virtual screening and subsequent in vitro validation. [Read the Full Post]
Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
60 views | Nov 14 2023
NUAK1 and NUAK2 promote cell survival and proliferation in prostate stromal cells, potentially contributing to stromal hyperplasia in benign prostatic hyperplasia (BPH), and their effects can be mimicked by inhibitors HTH01-015 and WZ4003, suggesting therapeutic relevance in BPH management. [Read the Full Post]
HSP70 attenuates neuronal necroptosis through the HSP90α-RIPK3 pathway following neuronal trauma
141 views | Nov 14 2023
Activation of HSP70 protects against necroptosis in neuronal trauma, with HSP90α-mediated regulation of RIPK3 and MLKL contributing to this protective effect. [Read the Full Post]
Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization
88 views | Nov 13 2023
The Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) is a phase II platform trial that employs genomic profiling and adaptive randomization to evaluate novel therapies for glioblastoma, with abemaciclib and neratinib showing improved progression-free survival compared to the control arm, although none of the experimental therapies demonstrated a significant overall survival benefit. [Read the Full Post]